Borrmann S Peto T Snow RW Gutteridge W White NJPLoS Med. 2008;5e227
Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.
Altmetric
Enter the destination URL
Or link to existing content
